Literature DB >> 12270114

Specificity of anti-human CD95 (APO-1/Fas) antibodies.

Ingo Schmitz1, Andreas Krueger, Sven Baumann, Sabine Kirchhoff, Peter H Krammer.   

Abstract

The CD95 (APO-1/Fas) death receptor plays an important role in many physiological and pathophysiological systems. Thus, the CD95 system contributes to activation-induced cell death. Therefore, reliable antibodies recognizing human CD95 are of great interest. Detection of CD95 expression often relies on antibodies, e.g., suitable for Western blotting. To detect CD95, we compared the specificity of nine different anti-human CD95 antibodies recognizing different epitopes by using postnuclear supernatants of four different cell lines. Only two of the antibodies tested, both directed against intracellular epitopes of human CD95, detected endogenous human CD95 by Western blotting. Therefore, we conclude that results obtained with other anti-CD95 antibodies should be treated with caution.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270114     DOI: 10.1016/s0006-291x(02)02242-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Adenovirus-mediated FasL gene transfer into human gastric carcinoma.

Authors:  Shi-Ying Zheng; De-Chun Li; Zhi-De Zhang; Jun Zhao; Jin-Feng Ge
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

2.  Modulation of the CD95-induced apoptosis: the role of CD95 N-glycosylation.

Authors:  Olga M Shatnyeva; Andriy V Kubarenko; Claudia E M Weber; Alexander Pappa; Reinhard Schwartz-Albiez; Alexander N R Weber; Peter H Krammer; Inna N Lavrik
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

3.  c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.

Authors:  Stephan Mathas; Andreas Lietz; Ioannis Anagnostopoulos; Franziska Hummel; Burkhard Wiesner; Martin Janz; Franziska Jundt; Burkhard Hirsch; Korinna Jöhrens-Leder; Hans-Peter Vornlocher; Kurt Bommert; Harald Stein; Bernd Dörken
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.